Discussion for evaluating 28-day mortality of severe COVID-19 patients treated with unfractionated heparin or low molecular weight heparin (LMWH) compared to control group
-
dosages used were relatively low, so researchers hypothesize higher doses may have stronger effects
-
anticoagulant treatment for sepsis-induced DIC is controversial
-
sepsis and coagulation patterns in COVID-19 cases may not be comparable to sepsis in other cases
-
treatment not randomly assigned
-
patients may not be representative due to limited supplies during outbreak period
-
treatments may have changed over the 6-week enrollment period
-
further studies are needed to evaluate effectiveness of anticoagulants in COVID-19 patients
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Differences in 28-day mortality of severe COVID-19 patients treated with unfractionated heparin or low molecular weight heparin (LMWH) compared to control group given no anticoagulant based on SIC score
Differences in 28-day mortality of severe COVID-19 patients by D-dimer level among those given unfractionated heparin or low molecular weight heparin (LMWH) compared to control group given no anticoagulant.
Evaluation of other predictors of 28-day mortality pertaining to clotting factors and heparin treatment
SIC score interpretation for COVID-19
Methods for evaluating heparin effectiveness in COVID-19 patients for patients at high risk of coagulopathy from retrospective study in Wuhan, China
Patient characteristics in study evaluating heparin effectiveness in COVID-19 patients for patients at high risk of coagulopathy from retrospective study in Wuhan, China
Discussion for evaluating 28-day mortality of severe COVID-19 patients treated with unfractionated heparin or low molecular weight heparin (LMWH) compared to control group